Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 13:10:5429-5437.
doi: 10.2147/OTT.S149197. eCollection 2017.

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

Junjun Lu #  1 , He Li #  2 , Peng Guo  1 , Rui Shen  3 , Yingbin Luo  1 , Qiao Ge  4 , Wenfei Shi  1 , Yan Li  1 , Weikang Zhu  1
Affiliations

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

Junjun Lu et al. Onco Targets Ther. .

Abstract

Objective: To evaluate the effect of CYP2D6 *10 polymorphism (C 100C>T, rs1065852) on clinical outcomes of female Asian breast cancer patients with tamoxifen adjuvant treatment.

Methods: Meta-analysis of retrospective cohort studies published in July 2017 was performed. Fifteen studies with 1,794 Asian breast cancer patients were included, using strict eligibility requirements. Associations of disease-free survival (DFS), overall survival (OS) and recurrence rate after tamoxifen intake, with CYP2D6 *10 polymorphism were investigated through random effects models.

Results: CYP2D6 *10 polymorphism was found to have effect on DFS and recurrence rate in various comparison models, but not on overall survival in the female Asian breast cancer patients.

Conclusion: In conclusion, our meta-analysis suggests that significant association of *10/*10 (TT) genotype with poorer DFS and recurrence exists in female Asian breast cancer patients with tamoxifen 20 mg/day adjuvant treatment. In the future, large and well-designed studies are required to illustrate the interactions of CYP2D6 genetic variants, including *10 polymorphism and tamoxifen response on female breast cancer patients.

Keywords: Asia; CYP2D6 *10; breast cancer; polymorphism; tamoxifen adjuvant treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study flow diagram for the process of selecting the final 15 studies.
Figure 2
Figure 2
Forest plot to estimate the effect of CYP2D6 *10 polymorphism on the DFS of breast cancer patients taking tamoxifen. Note: Weights are from random effects analysis. Abbreviations: DFS, disease-free survival; HR, hazard ratio.
Figure 3
Figure 3
Forest plot to estimate the effect of CYP2D6 *10 polymorphism on the recurrence of breast cancer in patients taking tamoxifen in the comparison of (A) TT vs CC; (B) CT/TT vs CC; (C) TT vs CT/TT and (D) T vs C allele. Note: Weights are from random effects analysis. Abbreviations: CI, confidence interval; OR, odds ratio.
Figure 4
Figure 4
Begg’s funnel plots to examine publication bias for reported comparisons of CYP2D6 *10 polymorphism with recurrence in the comparison of (A) CT vs CC and (B) TT vs CC in Asian breast cancer patients treated with tamoxifen. Abbreviations: OR, odds ratio; SE, standard error.
Figure 5
Figure 5
Sensitivity analysis of the comparison of allele genetic model (T vs C allele) in the recurrence analysis.
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. - PMC - PubMed
    1. Fabian C, Tilzer L, Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos. 1981;2(4):381–390. - PubMed
    1. Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 2013;23(11):643–647. - PMC - PubMed
    1. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8):1287–1293. - PMC - PubMed
    1. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429–1436. - PMC - PubMed